PortalPublikationenSuccessful treatment of refractory checkpoint inhibitor-indu...

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab

Standard

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab. / Hansen, Inga Pauline Marie; Kött, Julian; Heidenreich, Silke; Ayuk, Francis Ayuketang; Doll, Patricia Marie; Abeck, Finn; Booken, Nina; Gebhardt, Christoffer; Schneider, Stefan .

in: Journal of the European Academy of Dermatology and Venerology Clinical Practice, Jahrgang 3, Nr. 1, 01.03.2024, S. 317-320.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Case Report › Forschung › Begutachtung

Harvard

Hansen, IPM, Kött, J, Heidenreich, S, Ayuk, FA, Doll, PM, Abeck, F, Booken, N, Gebhardt, C & Schneider, S 2024, 'Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab', Journal of the European Academy of Dermatology and Venerology Clinical Practice, Jg. 3, Nr. 1, S. 317-320. https://doi.org/10.1002/jvc2.288

APA

Hansen, I. P. M., Kött, J., Heidenreich, S., Ayuk, F. A., Doll, P. M., Abeck, F., Booken, N., Gebhardt, C., & Schneider, S. (2024). Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab. Journal of the European Academy of Dermatology and Venerology Clinical Practice, 3(1), 317-320. https://doi.org/10.1002/jvc2.288

Vancouver

Hansen IPM, Kött J, Heidenreich S, Ayuk FA, Doll PM, Abeck F et al. Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab. Journal of the European Academy of Dermatology and Venerology Clinical Practice. 2024 Mär 1;3(1):317-320. https://doi.org/10.1002/jvc2.288

Bibtex

@article{8623bbbdf99943a3a5f26c291fdacea2,
title = "Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab",
abstract = "Immune checkpoint inhibitors have established in the treatment of malignant melanoma and have significantly improved prognosis in advanced tumour stages. As they interfere with immunoregulatory pathways by blocking checkpoints, nonspecific activation of the immune system can result in the development of immune-related adverse events. Hepatitis occurs in 25%–30% of combination therapy and usually occurs 6–12 weeks after initiation of treatment. In most cases, the adverse event can be successfully treated with glucocorticosteroids but sometimes this is not sufficient, and further therapy is required. We report on a life-threatening course of immune-mediated hepatitis in a 39-year-old woman with metastatic melanoma, whom we were finally able to treat successfully with a combination therapy consisting of prednisolone, mycophenolate-mofetil, extracorporeal photopheresis and infliximab.",
author = "Hansen, {Inga Pauline Marie} and Julian K{\"o}tt and Silke Heidenreich and Ayuk, {Francis Ayuketang} and Doll, {Patricia Marie} and Finn Abeck and Nina Booken and Christoffer Gebhardt and Stefan Schneider",
year = "2024",
month = mar,
day = "1",
doi = "10.1002/jvc2.288",
language = "English",
volume = "3",
pages = "317--320",
journal = "Journal of the European Academy of Dermatology and Venerology Clinical Practice",
issn = "2768-6566",
publisher = "John Wiley & Sons",
number = "1",

}

RIS

TY - JOUR

T1 - Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab

AU - Hansen, Inga Pauline Marie

AU - Kött, Julian

AU - Heidenreich, Silke

AU - Ayuk, Francis Ayuketang

AU - Doll, Patricia Marie

AU - Abeck, Finn

AU - Booken, Nina

AU - Gebhardt, Christoffer

AU - Schneider, Stefan

PY - 2024/3/1

Y1 - 2024/3/1

N2 - Immune checkpoint inhibitors have established in the treatment of malignant melanoma and have significantly improved prognosis in advanced tumour stages. As they interfere with immunoregulatory pathways by blocking checkpoints, nonspecific activation of the immune system can result in the development of immune-related adverse events. Hepatitis occurs in 25%–30% of combination therapy and usually occurs 6–12 weeks after initiation of treatment. In most cases, the adverse event can be successfully treated with glucocorticosteroids but sometimes this is not sufficient, and further therapy is required. We report on a life-threatening course of immune-mediated hepatitis in a 39-year-old woman with metastatic melanoma, whom we were finally able to treat successfully with a combination therapy consisting of prednisolone, mycophenolate-mofetil, extracorporeal photopheresis and infliximab.

AB - Immune checkpoint inhibitors have established in the treatment of malignant melanoma and have significantly improved prognosis in advanced tumour stages. As they interfere with immunoregulatory pathways by blocking checkpoints, nonspecific activation of the immune system can result in the development of immune-related adverse events. Hepatitis occurs in 25%–30% of combination therapy and usually occurs 6–12 weeks after initiation of treatment. In most cases, the adverse event can be successfully treated with glucocorticosteroids but sometimes this is not sufficient, and further therapy is required. We report on a life-threatening course of immune-mediated hepatitis in a 39-year-old woman with metastatic melanoma, whom we were finally able to treat successfully with a combination therapy consisting of prednisolone, mycophenolate-mofetil, extracorporeal photopheresis and infliximab.

U2 - 10.1002/jvc2.288

DO - 10.1002/jvc2.288

M3 - Case report

VL - 3

SP - 317

EP - 320

JO - Journal of the European Academy of Dermatology and Venerology Clinical Practice

JF - Journal of the European Academy of Dermatology and Venerology Clinical Practice

SN - 2768-6566

IS - 1

ER -